Rezolute's upLIFT Phase 3 Hits Primary Endpoint in Tumor Hyperinsulinism
RZLT has more than doubled off its 52-week low of $1.07.
Summary
Rezolute's Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism met its primary efficacy endpoint on preliminary data from a November 5th evaluation. Thirteen of 16 participants hit the responder bar — at least a 50% cut in glucose infusion rate — and 12 of those fully stopped IV glucose; statistical significance required at least 9 responders. That is a clean win for a program that had been overshadowed by the sunRIZE miss in congenital HI on November 2nd, and it keeps a second BLA path alive. Full topline results, including the formal statistical analysis, are due mid-December 2026, with FDA discussions planned for Q1 2027 ahead of potential BLA submissions in both tumor and congenital HI next year. The timing matters: the company launched a Morgan Stanley-led underwritten offering this morning with cash at $90.0M and has now priced a $100M public offering of common stock and pre-funded warrants, so a positive registrational read strengthens the equity story behind that raise. Watch the mid-December topline for the confidence interval and the three participants still in the pivotal period.
At the time of this announcement, RZLT was trading at $3.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $374.3M. The 52-week trading range was $1.07 to $11.17. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.